Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C24H32N2O5.H2O4S |
| Molecular Weight | 955.121 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CN(C)C(=O)COC1=CC=C2CC[C@@H](CC2=C1)NC[C@H](O)C3=CC=C(O)C(CCO)=C3.CN(C)C(=O)COC4=CC=C5CC[C@@H](CC5=C4)NC[C@H](O)C6=CC=C(O)C(CCO)=C6
InChI
InChIKey=VPCOODFYDJWLHD-YMZXMBPUSA-N
InChI=1S/2C24H32N2O5.H2O4S/c2*1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27;1-5(2,3)4/h2*4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3;(H2,1,2,3,4)/t2*20-,23-;/m00./s1
| Molecular Formula | C24H32N2O5 |
| Molecular Weight | 428.5213 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Bedoradrine (also known as KUR-1246 or MN-221), an ultra selective beta 2-adrenoceptor agonist, that participated in phase II clinical trials as an adjunct to standard therapy in the management of patients with acute exacerbation of asthma who did not respond to standard therapy. In addition, the drug was involved in trials for the treatment of preterm labor in obstetrical practice. Bedoradrine is also was studied in phase I of clinical trials for its use for treating chronic obstructive pulmonary disease, however, the efficacy for this disease was uncertain.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19527375 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. | 2009-06 |
|
| Effects of KUR-1246, a selective uterine relaxant, on transplacental passage and transmigration to milk. | 2006-02 |
|
| Cardiovascular effects of KUR-1246, a new tetrahydronaphthalen derivative beta2-adrenoceptor agonist and a selective uterine relaxant. | 2006 |
|
| Effects of long term administration of KUR-1246, a selective beta(2)-adrenoceptor agonist, on pregnant sheep and their fetuses. | 2005-01 |
|
| KUR-1246, a novel beta(2)-adrenoceptor agonist, as a tocolytic agent. | 2002-09 |
|
| Diversity of inhibitory responses to beta2-stimulants shown by term-pregnant human myometria in vitro is partly due to differences in receptor density. | 2002-05 |
|
| The practical synthesis of a uterine relaxant, bis(2-[[(2S)-2-([(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)-phenyl]ethyl]amino)-1,2,3,4-tetrahydronaphthalen-7-yl]oxy]-N,N-dimethylacetamide) sulfate (KUR-1246). | 2001-08 |
Patents
Sample Use Guides
Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:03:45 GMT 2025
by
admin
on
Mon Mar 31 18:03:45 GMT 2025
|
| Record UNII |
P875C0DV2V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000174949
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
PRIMARY | |||
|
194785-31-4
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
PRIMARY | |||
|
DTXSID40433338
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
PRIMARY | |||
|
DBSALT001988
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
PRIMARY | |||
|
P875C0DV2V
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
PRIMARY | |||
|
9963056
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
PRIMARY | |||
|
C77933
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
PRIMARY | |||
|
RR-91
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL2111083
Created by
admin on Mon Mar 31 18:03:45 GMT 2025 , Edited by admin on Mon Mar 31 18:03:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|